arrow
N

Norifumi Takeda

University of Tokyo
H指数:39
被引数:6,695

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

In Response to Quantifying the population burden of hypertension: methodological considerations on the PAF analysis of the DeSC cohort

针对量化高血压人群负担的回应:关于DeSC队列PAF分析的方<br>法学考量

2026-06-010
PRE
Association Between Cardiovascular-Kidney-Metabolic Syndrome and Cancer Development: Insights From a Nationwide Database Study in Japan

心血管-肾脏-代谢综合征与癌症发生的关系:来自日本全国数据库研究的见解

2026-05-010
PRE
Association of Weight Loss With Improvement in Metabolic Status Among People Eligible for the Specific Health Guidance Program

体重减轻与特定健康指导项目合格人群代谢状态改善的关联

2026-04-011
PRE
Evolving trends of antidiabetic agents stratified by age, kidney function and body mass index: Insights from a nationwide claims database

按年龄、肾功能和体重指数分层的降糖药物演变趋势:基于全国性索赔数据库的见解

2025-11-020
OAAI
Right ventricular systolic and diastolic parameters based on pressure–volume loop theory in heart failure

基于压力-容积环理论的心力衰竭右心室收缩和舒张参数

2025-10-100
OAAI
Reply to Comment on “Blood pressure control and treatment status at 1 year after the first health check-up in individuals with observed referral-level blood pressure”

回复关于“首次健康检查中观察到的转诊水平血压的个体在1年后的血压控制及治疗状况”的评论

2025-10-060
PRE
Low-Density-Lipoprotein Cholesterol Control and Treatment Status 1 Year after the Initial Health Checkup in Individuals with Referral-Level LDL Cholesterol

低密度脂蛋白胆固醇控制与治疗状况:在LDL胆固醇处于转诊水平的个体初次健康检查1年后的情况

2025-09-010
OA
Gender differences in the prescription of SGLT2 inhibitors in chronic kidney disease: A real-world database study

慢性肾脏病患者中SGLT2抑制剂处方的性别差异:一项真实世界数据库研究

2025-08-180
OA